Title:
POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR
Document Type and Number:
WIPO Patent Application WO2006060730
Kind Code:
A3
Abstract:
Potassium salts of Coompound A and methods for their preparation are disclosed, wherein Compound A is of formula: (Compound A). Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.
More Like This:
Inventors:
BELYK KEVIN M (US)
MORRISON HENRY G (US)
JONES PHILIP (IT)
SUMMA VINCENZO (IT)
COOPER V BRETT (GB)
MAHAJAN AMAR J (US)
KUMKE DANIEL J (US)
TUNG HSIEN-HSIN (US)
WAI LAWRENCE (US)
PRUZINSKY VANESSA (US)
PYE PHILIP (US)
ANGELAUD REMY (US)
MANCHENO DANNY (US)
MORRISON HENRY G (US)
JONES PHILIP (IT)
SUMMA VINCENZO (IT)
COOPER V BRETT (GB)
MAHAJAN AMAR J (US)
KUMKE DANIEL J (US)
TUNG HSIEN-HSIN (US)
WAI LAWRENCE (US)
PRUZINSKY VANESSA (US)
PYE PHILIP (US)
ANGELAUD REMY (US)
MANCHENO DANNY (US)
Application Number:
PCT/US2005/043781
Publication Date:
August 17, 2006
Filing Date:
December 02, 2005
Export Citation:
Assignee:
MERCK & CO INC (US)
ELETTI S P A ISTITUTO DI RICER (IT)
MERCK SHARP & DOHME (GB)
BELYK KEVIN M (US)
MORRISON HENRY G (US)
JONES PHILIP (IT)
SUMMA VINCENZO (IT)
COOPER V BRETT (GB)
MAHAJAN AMAR J (US)
KUMKE DANIEL J (US)
TUNG HSIEN-HSIN (US)
WAI LAWRENCE (US)
PRUZINSKY VANESSA (US)
PYE PHILIP (US)
ANGELAUD REMY (US)
MANCHENO DANNY (US)
ELETTI S P A ISTITUTO DI RICER (IT)
MERCK SHARP & DOHME (GB)
BELYK KEVIN M (US)
MORRISON HENRY G (US)
JONES PHILIP (IT)
SUMMA VINCENZO (IT)
COOPER V BRETT (GB)
MAHAJAN AMAR J (US)
KUMKE DANIEL J (US)
TUNG HSIEN-HSIN (US)
WAI LAWRENCE (US)
PRUZINSKY VANESSA (US)
PYE PHILIP (US)
ANGELAUD REMY (US)
MANCHENO DANNY (US)
International Classes:
C07D239/557; A61K31/513; A61P31/18; C07D413/12
Domestic Patent References:
WO2003035077A1 | 2003-05-01 |
Download PDF:
Previous Patent: FIELD SENSING NETWORK
Next Patent: USE OF ATAZANAVIR FOR IMPROVING THE PHARMACOKINETICS OF DRUGS METABOLIZED BY UGT1A1
Next Patent: USE OF ATAZANAVIR FOR IMPROVING THE PHARMACOKINETICS OF DRUGS METABOLIZED BY UGT1A1